We found higher median proportions of CD163-positive cells in the cancer group in CD14+16+ (98.08(86.40–100.00)%) and CD14low16+ (99.08(83.47–99.99)%) subsets compared to healthy women: 86.96(77.33–93.02)% for CD14+16+ (p = 0.049) and 60.00 (41.06–91.3)% for CD14low16+ (p = 0.004) cells (Figure 2). Here, CD163 is linked to cancer.